Key facts
- Notable investors include Thematic Technology Transfer, LifeSciences@Work.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Inborn (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for Inborn (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inborn (Drug Discovery)
Developer of nano particle-based inject able gels designed for localised antibacterial therapy in bone infection treatment. The company's platform incorporates hydrogenation and gelatin nanoparticles into a paste-like gel that is cytology and biocompatible, allows direct application to infection sites, enabling orthopaedic care providers to reduce systemic side effects and improve therapeutic outcomes for patients with recurrent bone infections.
- Sector
- Healthcare
- HQ
- Nijmegen, Netherlands
- Employees
- 2
- Website
- inbornbiomedical.com/
- Ownership
- Privately Held (backing)
Inborn (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inborn (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inborn (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.